Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

This study has been withdrawn prior to enrollment.
(Withdrawn by PI due to insufficient accrual)
Sponsor:
Collaborator:
Novartis
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00230334
First received: September 28, 2005
Last updated: April 11, 2011
Last verified: April 2011
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given